Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial.
Gomez-Lara J, Brugaletta S, Gomez-Hospital JA, Ferreiro JL, Roura G, Romaguera R, Martin-Yuste V, Masotti M, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Serruys P, Sabate M, Cequier A. Gomez-Lara J, et al. Among authors: brugaletta s. Am Heart J. 2013 Jul;166(1):119-26. doi: 10.1016/j.ahj.2013.04.012. Epub 2013 May 28. Am Heart J. 2013. PMID: 23816030 Clinical Trial.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Among authors: brugaletta s. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, Martí G, Cascant P, Martín-Yuste V, Brugaletta S, Sabaté M, Alfonso F, Capote ML, De La Torre JM, Ruíz-Lera M, Sanmiguel D, Cárdenas M, Pujol B, Baz JA, Iñiguez A, Trillo R, González-Béjar O, Casanova J, Sánchez-Gila J, García-Dorado D. Ferreira-González I, et al. Among authors: brugaletta s. Circulation. 2010 Sep 7;122(10):1017-25. doi: 10.1161/CIRCULATIONAHA.110.938290. Epub 2010 Aug 23. Circulation. 2010. PMID: 20733100 Clinical Trial.
ETHICA Award 2010: Antonio Colombo.
Serruys PW, Brugaletta S. Serruys PW, et al. Among authors: brugaletta s. EuroIntervention. 2010 Sep;6(4):431. doi: 10.4244/EIJ30V6I4A73. EuroIntervention. 2010. PMID: 20884428 No abstract available.
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, van Geuns RJ, McClean D, Dudek D, Thuesen L, Chevalier B, Windecker S, Whitbourn R, Dorange C, Miquel-Hebert K, Sudhir K, Ormiston JA, Serruys PW. Brugaletta S, et al. Int J Cardiovasc Imaging. 2011 Jul;27(6):859-66. doi: 10.1007/s10554-010-9724-y. Epub 2010 Oct 13. Int J Cardiovasc Imaging. 2011. PMID: 20941544 Free article. Clinical Trial.
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators. Campo G, et al. Among authors: brugaletta s. J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55. doi: 10.1016/j.jacc.2010.03.103. J Am Coll Cardiol. 2010. PMID: 20951320 Free article. Clinical Trial.
A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, van Geuns RJ, Dorange C, Veldhof S, Rapoza R, Whitbourn R, Windecker S, Garcia-Garcia HM, Regar E, Serruys PW. Gomez-Lara J, et al. Among authors: brugaletta s. Eur Heart J. 2011 Feb;32(3):294-304. doi: 10.1093/eurheartj/ehq458. Epub 2010 Dec 1. Eur Heart J. 2011. PMID: 21123276 Free article.
398 results